Niacin (vitamin B3): forms, food, pellagra, flushing, cholesterol trials, and NAD-related claims

Forms and units answer different questions

Food sources include grains, legumes and animal foods

MedlinePlus lists fish, poultry, lean meat, peanuts, legumes and enriched grain products among sources. Adequacy is a question about the overall dietary pattern, not whether someone buys a particular supplement. A nutrient in enriched bread is still a nutrient; comparing foods also requires considering their other constituents and the rest of the diet.[2]

Pellagra is a deficiency disease, not an expected effect of every restrictive diet

MedlinePlus describes pellagra as a consequence of inadequate niacin, with skin inflammation, digestive problems and impaired mental function. These manifestations can be serious, but similar symptoms can have other explanations. Diagnosing pellagra requires clinical and nutritional assessment; a symptom checklist or a transient response to a supplement cannot by itself establish the cause.[2]

Requirements are designed for healthy-population nutrition

MedlinePlus explains reference intakes for healthy people, with differences by age, sex, pregnancy and breastfeeding. These values are not cholesterol-treatment doses. Meeting ordinary nutrient needs and prescribing pharmacological amounts involve different benefit and safety questions. A label showing many times a reference intake is not evidence that the product supplies many times the health benefit.[2]

The European estimate is related to energy requirements

EFSA’s 2014 final opinion retained an energy-related average requirement based on urinary niacin metabolites, with a variability allowance for the population reference intake. It extended that relationship to other life stages under stated assumptions. The opinion describes the evidence basis for nutritional adequacy; it does not validate a personal “optimal NAD” blood target.[3]

A flush is an adverse effect, not a success marker

NIH describes warmth, redness, itching and related symptoms with supplemental nicotinic acid. A visible flush does not measure detoxification or prove a cardiovascular benefit. Larger amounts can create additional problems, including effects on blood pressure, glucose, vision and the liver. Nutrient status and tolerance of a high-dose preparation are separate issues.[1]

Less flushing does not mean unlimited safety

The MedlinePlus encyclopedia uses reassuring language about nicotinamide adverse effects. This is broader than a dose-specific safety claim.[2]

NIH describes gastrointestinal, bleeding-related or liver effects at sufficiently high amounts. The broader reassurance should not be read as “any dose is harmless.” Different forms and amounts have different safety profiles, and a no-flush label does not establish medical benefit.[1]

Medicines and nutrient handling can interact

NIH describes interactions involving tuberculosis medicines and concerns when high-dose niacin is combined with glucose-related treatment. These are reasons to review the actual product and medication list. A dietary source of B3, a routine supplement and a prescribed lipid-lowering preparation should not be treated as identical exposures.[1]

AIM-HIGH tested an addition to existing lipid treatment

In 2011, 3,414 participants with established cardiovascular disease were randomized to extended-release niacin or placebo alongside statin-based therapy. After about three years, the composite cardiovascular endpoint occurred in 16.4% and 16.2%, respectively: hazard ratio 1.02, 95% confidence interval 0.87–1.21. The trial stopped for lack of efficacy despite changes in cholesterol and triglycerides.[4]

The composite included several cardiovascular events and procedures, rather than only death. NHLBI and Abbott Laboratories funded the study. Its conclusion concerns adding niacin in that selected treatment setting; it is not a trial of treating pellagra, meeting dietary requirements or every currently marketed B3 derivative.[4]

Published questions

A second large trial tested a combination product

HPS2-THRIVE compared extended-release niacin plus laropiprant with placebo alongside statin-based treatment. Over a median 3.9 years, major vascular events occurred in 13.2% versus 13.7%: rate ratio 0.96, 95% confidence interval 0.90–1.03. That comparison did not show a significant reduction in events, even though lipid values changed. It studied a specific combination, not every B3 product.[5]

The trial found more serious adverse effects, including worsened diabetes control, new diabetes, gastrointestinal problems, infection and bleeding. Merck and others funded it. The combination and selected population matter when interpreting these findings. A supplement marketed as natural should not be presumed to avoid the benefit-versus-harm questions raised by pharmacological nutrient exposure.[5]

A synthesis reaches beyond either single trial

Cochrane’s 2017 review included 23 trials and 39,195 participants and did not find convincing reductions in mortality or major cardiovascular outcomes. Participants assigned niacin were more likely to stop because of adverse effects. The trials varied in prior disease and background treatment. Its certainty judgments belong to that review; the Atlas has not independently regraded the studies.[6]

The included trials were published between 1968 and 2015. This is a dated synthesis rather than a new search through 2026. It helps explain why favorable lipid changes did not establish a preventive benefit, while leaving newer products and other disease-specific uses outside this article’s appraisal.[6]

A shared precursor story does not settle a product claim

EFSA defines niacin equivalents partly through the body’s conversion of tryptophan. A conversion pathway explains why the unit includes more than dietary nicotinic acid alone. It does not establish that every compound marketed in the B3 or NAD category has identical absorption, biological effects or clinical benefit. Each proposed product and outcome needs its own evidence.[3]

References

1. Niacin: Consumer Fact Sheet

   Agency condition or prevention explanation

   NIH Office of Dietary Supplements · Content/publication date: not stated
   Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
   Cited sections: Forms, flushing, high-intake harms and medicine interactions

2. Niacin: Medical Encyclopedia

   Agency condition or prevention explanation

   A.D.A.M. clinical editors / MedlinePlus · Content/publication date: 2025
   Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
   Cited sections: January 21, 2025 clinical review: foods, pellagra and reference-intake framework

   Its broad nicotinamide reassurance is qualified using the NIH high-intake safety explanation.

3. Scientific Opinion on Dietary Reference Values for niacin

   Agency scientific opinion

   EFSA NDA Panel · Content/publication date: 2014
   Accessed: 2026-10-09 UTC · Original final-opinion abstract inspected; full underlying evidence appraisal pending
   Cited sections: Final July 2014 abstract: forms, tryptophan equivalents and requirement assumptions

4. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

   Randomized trial

   AIM-HIGH Investigators · Content/publication date: 2011
   Accessed: 2026-10-09 UTC · Original full abstract inspected; full eligibility, correspondence and safety appraisal pending
   Cited sections: 2011: 3,414 participants, composite endpoint, lipid changes, stopping and funding

5. Effects of extended-release niacin with laropiprant in high-risk patients

   Randomized trial

   HPS2-THRIVE Collaborative Group · Content/publication date: 2014
   Accessed: 2026-10-09 UTC · Original selected abstract results and conclusions inspected; complete combination-specific harm attribution pending
   Cited sections: 2014: combination treatment, vascular outcomes, serious harms and funding

6. Niacin for primary and secondary prevention of cardiovascular events

   Systematic review

   Schandelmaier S and colleagues / Cochrane · Content/publication date: 2017
   Accessed: 2026-10-09 UTC · Original review summary and selected methods/results inspected; no independent full-text appraisal
   Cited sections: 2017: trial dates, 23 trials, clinical outcomes and adverse-effect discontinuation

   Dated synthesis; no independent Atlas evidence grade.

Scope & review

Population

Readers exploring B3 nutrition and products; selected statin-treated cardiovascular trial populations are distinguished

Exposure or intervention

Forms, nutrient adequacy, high-dose harms and lipid versus clinical-event evidence

Comparison

Source-specific symptom, care, screening or comparator settings

Outcomes

Deficiency, lipid markers, cardiovascular events, mortality and adverse effects

Timeframe

Regular dietary intake; dated clinical trials over approximately three-to-four years

Jurisdiction

Selected US/UK agency and US/European professional guidance; jurisdiction and eligibility differences are labeled

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

What this article still leaves open

• Current lipid guidelines, newer B3 derivatives, skin-cancer-specific nicotinamide trials and full sponsor/correspondence appraisal need expansion.
• NAD-targeted products, laboratory claims and long-term high-dose safety require product-specific articles and evidence.
• Qualified review, personal nutrient diagnosis and supplement or lipid-treatment regimens are not supplied.

Related reading

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.